Biotech vet MacKay grabs a $25M A round to back a gene therapy upstart
After completing an 11-year stint as CEO of Organogenesis, Geoff MacKay gathered a small, experienced team together and began a global search for new gene therapies at AvroBio. Earlier this year, they landed seed financing from Atlas Venture after zeroing in on the work of a pair of scientists in Toronto. And today he landed a $25 million A round to get his two lead programs into the clinic later this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.